Skip to main content
2025 SECO Annual Congress Main banner
Back

SECO 2025

AOA CE HOURS

COPE-TD

CEE-TQ

OD FL

OD IL

OD SC

OD TX

AOA-PARA

NCLE

OPT AZ

OPT NV

OPT TN

63 - Hot Topic Breakfast - The Future of Dry Eye Management: Perspectives from Leading Experts

Saturday, March 1, 2025
8:00 AM – 10:45 AM EST
Location: Georgia World Congress Center, 411/412
CE Hours: 2
Join us for an engaging panel discussion led by experts on the latest advancements and key debates in dry eye disease. We will cover common anterior segment conditions that share symptoms and clinical signs with dry eye disease. Case studies will highlight practical insights for practitioners to accurately diagnose and offer effective treatments. Treatment options to be discussed include topical and oral medications, amniotic membranes, intense pulsed light, and surgical interventions and more.

Learning Objectives:

Upon conclusion of this activity, attendees will be able to:
  • Learn how to examine patients for dry eye disease.
  • Understand the latest advancements in the research pipeline for ocular conditions.
  • Learn about the relationship between dry eye disease and glaucoma management.
  • Understand how glaucoma medications affect tear film stability and dry eye symptoms.
  • Implement post-operative protocols to effectively manage dry eye in surgical patients.
  • Recognize the potential effects of cosmetics on ocular surface health and dry eye symptoms.
Disclosure(s):
Melissa Barnett, OD: ABBOptical: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); AbbVie/Allergan: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Acculens: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Azura Ophthalmics: Advisory Committee/Board Member (); Bausch + Lomb: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); BCLA: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Bruno Vision Care: Advisory Committee/Board Member (); CooperVision: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Gas Permeable Lens Institute: Advisory Committee/Board Member (); Johnson & Johnson Vision: Advisory Committee/Board Member (); Lentechs: Advisory Committee/Board Member (); Ocusoft: Advisory Committee/Board Member (); Orasis: Advisory Committee/Board Member (); Percept: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); RVL: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Science Based Health: Consulting Fees (); Sjogren's Syndrome Foundation: Advisory Committee/Board Member (); STAPLE program: Speaker's Bureau (honoraria or other compensation) (); Tarsus: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Thea Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Visus Therapeutics: Advisory Committee/Board Member (), Consulting Fees ()
Selina McGee, OD: Harrow: Advisory Committee/Board Member (), Consulting Fees (); Nordic: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Sydnexis: Consulting Fees ()
Jaci Theis, OD, FAAO: C. Light Technologies: Advisory Committee/Board Member (), Employee (paid via salary or other compensation such as stock options) (); Dompe: Speaker's Bureau (honoraria or other compensation) (); Myze: Advisory Committee/Board Member (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Tarsus: Speaker's Bureau (honoraria or other compensation) (); Vision Science Labs: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) ()
Justin Schweitzer, OD: AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (), Consulting Fees (); Dompe: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Eyenovia Bio: Consulting Fees (); Glaukos: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Heru: Consulting Fees (); Iveric Bio: Consulting Fees (); LKC: Advisory Committee/Board Member (), Consulting Fees (); Mediprint: Advisory Committee/Board Member (), Consulting Fees (); Ocuphire: Advisory Committee/Board Member (), Consulting Fees (); Reichert: Consulting Fees (); Santen: Consulting Fees (); Science Based Health: Advisory Committee/Board Member (), Consulting Fees (); Sight Sciences: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Sun Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Thea Pharma: Consulting Fees (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member (), Consulting Fees (); ZEISS: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) ()
Breanne McGhee, OD, PhD, MEd: No financial relationships to disclose